Your browser doesn't support javascript.
loading
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá, M; Brunet, S; Nomdedéu, J; Cordeiro, A; Tormo, M; Escoda, L; Ribera, J M; Arnan, M; Heras, I; Gallardo, D; Bargay, J; Queipo de Llano, M P; Salamero, O; Martí, J M; Sampol, A; Pedro, C; Hoyos, M; Pratcorona, M; Castellano, J J; Nomdedeu, M; Risueño, R M; Sierra, J; Monzó, M; Navarro, A; Esteve, J.
Afiliación
  • Díaz-Beyá M; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
  • Brunet S; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Nomdedéu J; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Cordeiro A; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.
  • Tormo M; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Escoda L; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.
  • Ribera JM; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain.
  • Arnan M; Hematology Department, Hospital Clínico, Valencia, Spain.
  • Heras I; Hematology Department, Hospital Joan XXIII, Tarragona, Spain.
  • Gallardo D; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Bargay J; Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain.
  • Queipo de Llano MP; ICO, Hematology Department, Hospital Duran i Reynals, l'Hospitalet de Llobregat, Barcelona, Spain.
  • Salamero O; Hematology Department, Hospital Morales Meseguer, Murcia, Spain.
  • Martí JM; Hematology Department, ICO Josep Trueta, Girona, Spain.
  • Sampol A; Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca Hematology, Palma de Mallorca, Spain.
  • Pedro C; Hematology Department, Hospital Virgen de la Victoria, Malaga, Spain.
  • Hoyos M; Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain.
  • Pratcorona M; Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain.
  • Castellano JJ; Hematology Department, Hospital de Son Llàtzer, Palma of Mallorca, Spain.
  • Nomdedeu M; Hematology Department, Hospital de Mar, Barcelona, Spain.
  • Risueño RM; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.
  • Sierra J; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
  • Monzó M; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Navarro A; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain.
  • Esteve J; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
Blood Cancer J ; 5: e352, 2015 Oct 02.
Article en En | MEDLINE | ID: mdl-26430723
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Biomarcadores de Tumor / MicroARNs / Proteínas de Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2015 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Biomarcadores de Tumor / MicroARNs / Proteínas de Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2015 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos